The global Antiviral Drugs Market Size is expected to be worth $59,596.8 million in 2022. Throughout the forecast period, the introduction of generic antiviral medicines, as well as increased awareness about the availability of various vaccines for viral infections, are affecting growth. The overall demand for Anti-Viral Drugs is expected to grow at a CAGR of 3.9% between 2022 and 2032, reaching around US$ 87,675.36 Million.
Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1951
Anti-viral medications are medications that are used to treat viral infections. Unlike antibiotics, most anti-viral drugs are used to treat specific viral infections, whereas a broad-spectrum anti-viral drug is effective against a wide range of viruses. Antiviral drugs do not kill the pathogens they target; rather, they inhibit their growth.
Because of increased awareness, an increase in diseased population, and the introduction of new drugs with improved efficacy, the global anti-viral drugs market is expected to grow at a moderate rate in the pharmaceutical market.
Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.
Late-stage pipeline drugs are expected to enter the market, which will have a positive impact on the market. Because most antivirals are considered relatively harmless to the host, they are used to treat infections. They are not medications, but they can destroy or deactivate virus particles both outside and inside the body.
Patients with herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses are treated with antiviral drugs.
Anti-viral Drugs Market: Drivers and Restraints
As of October 2013, approximately 35.3 million people worldwide were infected with HIV, according to the WHO. As a result, rising viral infection rates are one of the primary factors driving the growth of the anti-viral drugs market. As a result of the strong R&D activities, newer and more advanced treatments and formulations, such as vaccines, combination therapy, and others, are being introduced to the market.
As a result, strong R&D is one of the critical factors in the growth of the anti-viral drugs market. High failure risk, high R&D and therapy costs, and government austerity are among the threats that are expected to stymie market growth.
These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1951
Anti-viral Drugs Market: Overview
Didanosine, zidovudine, lamivudine, and stavudine currently dominate the anti-viral generic market. HIV/AIDS therapeutic sales drove the overall anti-viral drug market, accounting for more than half of the market share in 2010.
Antiretroviral therapy was being administered to 9.7 million people in low- and middle-income countries by the end of 2012. (ART). The number of patients on ART increased by 1.6 million in 2012, according to WHO, the largest increase in a single year.
Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.
Anti-viral Drugs Market: Regional Overview
The global anti-viral drugs market is divided into five regions: North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, the Middle East, and Africa. According to WHO, in countries where major ART scale-up has occurred, such as Brazil or China, the death rate among HIV-positive people has decreased by 80%. In 2015, India had 2.1 million people living with HIV, while the United States had around 1.2 million in 2013.
Anti-viral Drugs Market: Key Players
Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.
Ask For Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-1951
Key Segments Covered in the Anti-Viral Drugs Industry Analysis
Anti-Viral Drugs Market by Product type:
- Hepatitis-C antivirals
- HIV antivirals
- Herpes antivirals
- Hepatitis-B antivirals
- Influenza antivirals
- Others (Pneumonia, Flu, etc.)
Anti-Viral Drugs Market by End-user:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs